PIII · XBRL financial data

P3 Health Partners financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PIII's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2024†Dec 31, 2025
Revenue from contracts with customers	—	1,049	1,266	1,500	1,459
General and administrative	—	157	122	113	106
Total operating expenses	—	2,610	1,434	1,821	1,729
Operating income (loss)	—	(1,561)	(168)	(321)	(270)
Other income (expense)	—	3	(0)	1	(3)
Income tax expense (benefit)	—	2	3	4	2
Net income (loss)	—	(270)	(58)	(136)	(148)
Earnings per share, basic USD per share	—	(6.50)	(0.61)	(0.94)	(45.26)
Earnings per share, diluted USD per share	—	(6.50)	(0.63)	(1.08)	(45.26)
Weighted average shares, basic millions of shares	—	0	95	145	3
Weighted average shares, diluted millions of shares	—	0	295	147	3

† Share count changed about 7085x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/2 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/45 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (PIII's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2024†Dec 31, 2025
Cash and cash equivalents	140	18	36	39	25
Prepaid and other current assets	7	3	4	14	11
Total current assets	200	101	166	184	133
Property and equipment, net	8	9	9	6	3
Right-of-use asset	7	12	15	13	13
Goodwill	1,310	0	—	—	—
Total assets	2,364	877	861	783	657
Accounts payable	5	12	9	8	12
Accrued liabilities	—	17	37	29	42
Current portion of long-term debt	0	0	0	65	45
Total current liabilities	199	242	299	496	545
Long-term debt	80	94	108	90	228
Lease liability, non-current	6	12	14	11	11
Total liabilities	300	354	427	634	797
Accumulated deficit	(39)	(310)	(367)	(503)	(651)
Total stockholders' equity	274	6	142	76	(155)
Total liabilities and equity	2,364	877	861	783	657

† Share count changed about 7085x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/2 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/45 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (PIII's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2024†Dec 31, 2025
Net income (loss)	—	(270)	(58)	(136)	(148)
Stock-based compensation	—	19	6	6	6
Net cash from operating activities	—	(126)	(76)	(110)	(91)
Purchases of property and equipment	—	2	2	0	—
Net cash from investing activities	—	(8)	(2)	15	0
Proceeds from long-term debt	—	15	14	88	73
Repayments of long-term debt	—	0	0	31	1
Net cash from financing activities	—	11	100	99	73
Net change in cash	—	(122)	22	3	(18)

† Share count changed about 7085x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/2 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/45 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 8000 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8000 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
P3 Health Partners	21	386	(62)*	not reported	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Longduoduo	1.6	0.6*	0.3*	30.0M	—	Q4 FY26 10-KJun 30, 2026
Vsee Health	0.5	1.6	(1.2)*	56.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Agape ATP	0	0.1	(0.1)*	1.0M	0.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.